在遗传前叶退化症中,明显的蛋白质性脑脊髓形状
Julie F H De Houwer1, Elise G Dopper1, Renee van Buuren1
1Department of Neurology and Alzheimer Centre, Erasmus MC University Medical Centre, Rotterdam 3015 GD, The Netherlands.
Brain : a journal of neurology
|December 4, 2025
概括
研究人员确定了脑脊液 (CSF) 中的特定蛋白质变化,以诊断前叶退化 (FTLD). 开发了两个诊断面板,显示了早期FTLD检测和区分FTLD亚型的前景.
科学领域:
- 神经科学是一个神经科学.
- 蛋白质组学是指蛋白质组学.
- 生物标志物发现发现
背景情况:
- 前叶退化 (FTLD) 缺乏可靠的液体生物标志物用于诊断.
- 了解脑脊液 (CSF) 中的蛋白质变化对于识别FTLD亚型和进展至关重要.
- 遗传因素显著影响FTLD病原体,需要对子组进行特定调查.
研究的目的:
- 在CSF中识别与不同基因组的FTLD病原体相关的独特蛋白质签名.
- 发现能够将FTLD频谱障碍与健康对照区分开来的蛋白质.
- 开发和验证FTLD和具有TDP病理的FTLD的基于蛋白质的诊断面板.
主要方法:
- 利用近距离延伸测试技术测量了来自两个FTLD队列的CSF中的2900多种蛋白质.
- 采用线性回归和过度表示分析来评估差异丰富的蛋白质和生物通路.
- 应用LASSO回归来开发和验证FTLD和FTLD-TDP的诊断面板.
主要成果:
- 在有症状的FTLD携带者中确定了23种失调的蛋白质,NEFL和TPM3在队列中始终显著.
- 在MAPT,C9orf72和GRN基因子组中发现了不同的蛋白质组签名,分别与免疫功能,能量代谢和神经元发育有关.
- 开发并验证了两个诊断面板 (FTLD面板:6种蛋白质;TDP面板:7种蛋白质),在区分FTLD患者和对照者方面具有高准确性 (AUC0.94-0.96).
结论:
- 在FTLD遗传子组和病理中存在不同的蛋白质组签名.
- 开发的基于CSF的新型蛋白质组面板为改善FTLD频谱障碍的临床诊断提供了有前途的工具.
- 这种有针对性的蛋白质组方法有助于更好地了解FTLD的病原和生物标志物发现.
关键词:
痴呆症 痴呆症是一种痴呆症.一个家庭的家庭的家庭.前性痴呆症前性痴呆症奥林克·奥林克·奥林克·奥林克·奥林克·奥林克·奥林克·奥林克·奥林克·奥林克·奥林克·奥林克·奥林克·奥林克·奥林克·奥林克蛋白质组是一种蛋白质组.基于近距离延伸的测试.更多相关视频
相关概念视频
01:11Genetic Lingo
Overview
01:37Neural Regulation
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
03:03Amyloid Fibrils
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...